NCT05764642

A Study of Renal Microvessel Imaging for Chronic Kidney Disease

Renal Microvessel Imaging for Characterization of Chronic Kidney Disease

• Status: Enrolling By Invitation
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 186 (estimated)
• Sponsor: Mayo Clinic · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The purpose of this research is to study the efficacy of ultrasound microvessel imaging for evaluation of Chronic Kidney Disease. Definity is an ultrasound contrast agent currently approved by the FDA for use on the heart, liver, and urinary tract. This study will look at its effectiveness on the kidney.

Conditions

• Healthy
• Chronic Kidney Diseases

Interventions

Type	Name	Description
DRUG	Definity	Ultrasound contrast agent administered intravenously
DIAGNOSTIC_TEST	Super-resolution ultrasound imaging	Imaging technology for microvessel imaging. This technology localizes and tracks individual microbubbles (FDA approved ultrasound contrast agents) to map microvessel morphology and flow speed at a spatial resolution about 10 times higher than conventional ultrasound imaging.

Timeline

• Start date: 2023-08-09
• Primary completion: 2028-04-01
• Completion: 2028-04-01
• First posted: 2023-03-10
• Last updated: 2025-09-05

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study
• FDA-regulated device study